Investor Information

Corporate Profile

BASi provides drug discovery and development services and analytical instruments that help pharmaceutical, biotechnology, leading academic institutions and government organizations in their drug development and research efforts. Our mission is to provide drug developers with superior scientific research and innovative analytical instrumentation, which saves time, saves money, and saves lives, to bring revolutionary new drugs to market quickly and safely. Our strategy is to provide services that will generate high-quality and timely data in support of new drug approval or use expansion. To learn more about our portfolio of services and analytical instruments, click here.

Click here to listen to BASi/Inotiv’s presentation at the H.C. Wainwright 22nd Annual Global Investment Conference. Our presentation begins at 2:30 p.m. EDT on September 16.

SEC Filings | Section 16 Filings

Market Quotes by TradingView

 

 

 

Investor Relations
Jill Blumhoff
Chief Financial Officer
765.497.8381
Email

BASi Reports First Quarter Results of Fiscal 2020‚Äč 

Friday, February 14, 2020 

 Results 

Annual Shareholders Meeting

March 19, 2020 - 10:30 am

Courtyard Marriott Lafayette

150 Fairington Avenue, Lafayette, IN 47905